CompletedPhase 3NCT02818738
Efficiency of Levamisole for Maintaining Remission After the First Flare of Steroid Sensitive Nephrotic Syndrome in Children
Studying Idiopathic steroid-sensitive nephrotic syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Assistance Publique - Hôpitaux de Paris
- Principal Investigator
- Claire DOSSIER, MDAssistance Publique - Hôpitaux de Paris
- Intervention
- Levamisole Hydrochloride(drug)
- Enrollment
- 86 enrolled
- Eligibility
- 16 years · All sexes
- Timeline
- 2017 – 2021
Study locations (1)
- Hôpital Robert Debré, Paris, France
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02818738 on ClinicalTrials.govOther trials for Idiopathic steroid-sensitive nephrotic syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2, PHASE3NCT07499700A Clinical Study of BAT4406F Injection in Patients With Minimal Change Disease/Focal Segmental GlomerulosclerosisBio-Thera Solutions
- RECRUITINGNCT03949972The FOrMe Registry (The German Focal Segmental Glomerulosclerosis and Minimal Change Disease Registry)Prof. Dr. Paul Brinkkoetter
See all trials for Idiopathic steroid-sensitive nephrotic syndrome →